Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Atara Biotherapeutics Inc ATRA

Healthcare Biotechnology
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel... see more

Recent & Breaking News (NDAQ:ATRA)

Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 13, 2023

Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Business Wire January 4, 2023

Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty

Business Wire December 20, 2022

Atara Biotherapeutics Announces Changes to Its Board of Directors

Business Wire December 19, 2022

Atara Biotherapeutics' Ebvallo(TM) (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD

Business Wire December 19, 2022

Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 15, 2022

Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting

Business Wire December 12, 2022

Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 2, 2022

Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference

Business Wire November 23, 2022

Atara Biotherapeutics to Participate at the Stifel Healthcare Conference

Business Wire November 9, 2022

Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress

Business Wire November 8, 2022

Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 4, 2022

Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

Business Wire November 1, 2022

Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022

Business Wire October 26, 2022

CHMP Recommends Approval of Atara Biotherapeutics' Ebvallo(TM) (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

Business Wire October 14, 2022

Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 10, 2022

Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre

Business Wire September 28, 2022

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Citigroup 17th Annual Biopharma Conference

Business Wire August 31, 2022

Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update

Business Wire August 8, 2022

ATARA ALERT: Bragar Eagel & Squire, P.C. is Investigating Atara Biotherapeutics, Inc. on Behalf of Atara Stockholders and Encourages Investors to Contact the Firm

Business Wire August 5, 2022